Minerva Neurosciences, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | $0 | $0 | $0 | $0 |
| Research and development | $5.8M | $11.9M | $12.7M | $14.6M | $32.0M |
| Operating expenses | $15.1M | $21.8M | $23.1M | $25.2M | $45.4M |
| Operating income | -$15.1M | -$21.8M | -$23.1M | -$25.2M | -$45.4M |
| Pretax income | — | — | — | -$32.1M | -$51.7M |
| Income tax expense | — | — | — | — | -$1.8M |
| Net income | -$293.4M | $1.4M | -$30.0M | -$32.1M | -$49.9M |
| Balance Sheet | |||||
| Cash and equivalents | $82.3M | $21.4M | $40.9M | $36.1M | $60.8M |
| Current assets | $83.1M | $22.3M | $42.0M | $40.2M | $62.2M |
| Total assets | $98.0M | $37.1M | $56.9M | $55.1M | $77.1M |
| Current liabilities | $2.3M | $2.8M | $3.3M | $1.4M | $2.8M |
| Total liabilities | $233.8M | $62.8M | $85.4M | $75.1M | $69.1M |
| Stockholders' equity | -$140.7M | -$25.7M | -$28.5M | -$20.0M | $8.0M |
| Cash Flow Statement | |||||
| Cash from operations | -$13.5M | -$19.6M | -$14.8M | -$24.6M | -$24.6M |
| Depreciation and amortization | $5,442 | $5,442 | $5,442 | — | — |
| Stock-based compensation | $1.3M | $1.3M | $2.0M | $4.1M | $5.2M |
| Capital expenditure | — | — | — | $16,326 | — |
| Free cash flow | — | — | — | -$24.7M | — |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 46.6M · Free float 84.6%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.